This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Kalydeco
  • /
  • A Study to Evaluate the Safety, Pharmacokinetics, ...
Clinical trial

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have a CFTR Gating Mutation

Read time: 2 mins
Last updated:1st Mar 2016
Identifier: NCT02725567

The purpose of this study is to evaluate the safety of ivacaftor treatment, and PK of ivacaftor and metabolites in subjects with cystic fibrosis (CF) who are <24 months of age at treatment initiation and have a CF transmembrane conductance regulator (CFTR) gene gating mutation


Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 35 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3, 2 Part, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have a CFTR Gating Mutation
Actual Study Start Date: March 2016
Estimated Primary Completion Date: June 2020
Estimated Study Completion Date: June 2020

Arms:
- Experimental:
Part A
- Experimental: Part B

Category Value
Date last updated at source 2019-01-16
Study type(s) Interventional
Expected enrolment 35
Study start date 2016-03-01
Estimated primary completion date 2020-06-01

View full details